ADMA Biologics(ADMA)
$13.19+0.52 (+4.10%)
ADMA
ADMA Biologics financials statements
$13.19
At close:+0.52 (+4.10%)
Want to see ADMA full AI Analyst Report?
ADMA Biologics (ADMA) Ratios
3,059 Followers
ADMA Biologics Ratios
ADMA's free cash flow for Q3 2026 was $15.37M. For the 2026 fiscal year, ADMA's free cash flow was decreased by $-2.00M and operating cash flow was $17.37M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 6.71 | 5.97 | 5.16 | 6.89 | 6.87 |
| Quick Ratio | 3.74 | 2.90 | 1.69 | 2.73 | 2.77 |
| Cash Ratio | 1.26 | 1.86 | 1.03 | 2.20 | 1.68 |
| Solvency Ratio | 1.06 | 1.47 | -0.10 | -0.30 | -0.49 |
| Operating Cash Flow Ratio | 0.72 | 2.14 | 0.18 | -1.52 | -3.70 |
| Short-Term Operating Cash Flow Coverage | 17.92 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 319.59M | $ 191.75M | $ 63.04M | $ 73.92M | $ 73.65M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.13 | 0.17 | 0.43 | 0.44 | 0.37 |
| Debt-to-Equity Ratio | 0.17 | 0.24 | 1.05 | 1.02 | 0.73 |
| Debt-to-Capital Ratio | 0.14 | 0.19 | 0.51 | 0.50 | 0.42 |
| Long-Term Debt-to-Capital Ratio | 0.13 | 0.17 | 0.49 | 0.48 | 0.40 |
| Financial Leverage Ratio | 1.31 | 1.40 | 2.43 | 2.29 | 1.96 |
| Debt Service Coverage Ratio | 16.34 | 15.77 | 0.20 | -2.05 | -4.07 |
| Interest Coverage Ratio | 26.93 | 9.98 | 0.86 | -2.04 | -4.47 |
| Debt to Market Cap | 0.02 | 0.02 | 0.13 | 0.19 | 0.48 |
| Interest Debt Per Share | 0.37 | 0.41 | 0.74 | 0.88 | 0.83 |
| Net Debt to EBITDA | -0.04 | -0.14 | 17.59 | -1.72 | -0.98 |
| Profitability Margins | |||||
| Gross Profit Margin | 57.39% | 51.48% | 34.44% | 22.89% | 1.45% |
| EBIT Margin | 37.20% | 32.75% | -1.24% | -30.26% | -72.39% |
| EBITDA Margin | 38.78% | 34.63% | 1.98% | -25.64% | -65.60% |
| Operating Profit Margin | 37.53% | 32.59% | 8.38% | -25.55% | -72.12% |
| Pretax Profit Margin | 35.80% | 29.48% | -10.94% | -42.77% | -88.52% |
| Net Profit Margin | 28.80% | 46.35% | -10.94% | -42.77% | -88.52% |
| Continuous Operations Profit Margin | 28.80% | 46.35% | -10.94% | -42.77% | -88.52% |
| Net Income Per EBT | 80.44% | 157.24% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 95.41% | 90.45% | -130.54% | 167.42% | 122.74% |
| Return on Assets (ROA) | 23.54% | 40.45% | -8.58% | -18.91% | -25.94% |
| Return on Equity (ROE) | 30.78% | 56.64% | -20.89% | -43.37% | -50.75% |
| Return on Capital Employed (ROCE) | 34.51% | 32.09% | 7.74% | -12.73% | -23.74% |
| Return on Invested Capital (ROIC) | 27.57% | 32.00% | 7.71% | -12.69% | -23.68% |
| Return on Tangible Assets | 23.70% | 40.78% | -8.68% | -19.16% | -26.44% |
| Earnings Yield | 3.38% | 4.95% | -2.79% | -8.58% | -36.41% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.22 | 8.53 | 9.42 | 9.94 | 2.83 |
| Payables Turnover | 9.65 | 10.23 | 10.81 | 8.98 | 6.42 |
| Inventory Turnover | 1.05 | 1.22 | 0.98 | 0.73 | 0.64 |
| Fixed Asset Turnover | 7.11 | 6.73 | 4.07 | 2.24 | 1.39 |
| Asset Turnover | 0.82 | 0.87 | 0.78 | 0.44 | 0.29 |
| Working Capital Turnover Ratio | 1.52 | 1.77 | 1.18 | 0.75 | 0.52 |
| Cash Conversion Cycle | 422.17 | 307.44 | 377.83 | 497.69 | 642.68 |
| Days of Sales Outstanding | 113.35 | 42.79 | 38.76 | 36.73 | 128.86 |
| Days of Inventory Outstanding | 346.63 | 300.32 | 372.83 | 501.60 | 570.69 |
| Days of Payables Outstanding | 37.81 | 35.67 | 33.77 | 40.64 | 56.87 |
| Operating Cycle | 459.98 | 343.11 | 411.59 | 538.33 | 699.56 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.21 | 0.51 | 0.04 | -0.30 | -0.81 |
| Free Cash Flow Per Share | 0.12 | 0.47 | 0.02 | -0.37 | -0.90 |
| Dividend Paid and CapEx Coverage Ratio | 2.23 | 13.84 | 1.77 | -4.28 | -8.32 |
| Capital Expenditure Coverage Ratio | 2.23 | 13.84 | 1.77 | -4.28 | -8.32 |
| Operating Cash Flow Coverage Ratio | 0.63 | 1.45 | 0.06 | -0.39 | -1.09 |
| Operating Cash Flow to Sales Ratio | 0.10 | 0.28 | 0.03 | -0.39 | -1.39 |
| Free Cash Flow Yield | 0.64% | 2.75% | 0.38% | -9.56% | -63.96% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 29.42 | 20.18 | -35.85 | -11.65 | -2.75 |
| Price-to-Sales (P/S) Ratio | 8.52 | 9.37 | 3.92 | 4.98 | 2.43 |
| Price-to-Book (P/B) Ratio | 9.11 | 11.45 | 7.49 | 5.05 | 1.39 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 156.23 | 36.31 | 265.09 | -10.46 | -1.56 |
| Price-to-Operating Cash Flow Ratio | 86.25 | 33.68 | 115.04 | -12.90 | -1.75 |
| Price-to-Earnings Growth (PEG) Ratio | -1.09 | -0.03 | 0.51 | 0.39 | 0.07 |
| Enterprise Value Multiple | 21.93 | 26.92 | 215.32 | -21.15 | -4.68 |
| Enterprise Value | 4.34B | 3.98B | 1.10B | 835.67M | 248.64M |
| EV to EBITDA | 21.93 | 26.92 | 215.32 | -21.15 | -4.68 |
| EV to Sales | 8.50 | 9.32 | 4.27 | 5.42 | 3.07 |
| EV to Free Cash Flow | 155.96 | 36.12 | 288.67 | -11.38 | -1.98 |
| EV to Operating Cash Flow | 86.09 | 33.51 | 125.28 | -14.04 | -2.21 |
| Tangible Book Value Per Share | 1.99 | 1.48 | 0.59 | 0.75 | 0.97 |
| Shareholders’ Equity Per Share | 2.00 | 1.50 | 0.60 | 0.77 | 1.01 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.20 | -0.57 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 2.14 | 1.83 | 1.15 | 0.78 | 0.58 |
| Net Income Per Share | 0.62 | 0.85 | -0.13 | -0.33 | -0.51 |
| Tax Burden | 0.80 | 1.57 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.96 | 0.90 | 8.79 | 1.41 | 1.22 |
| Research & Development to Revenue | 0.01 | 0.00 | 0.01 | 0.02 | 0.05 |
| SG&A to Revenue | 0.18 | 0.17 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.04 | 0.03 | 0.02 | 0.03 | 0.04 |
| Income Quality | 0.34 | 0.60 | -0.31 | 0.90 | 1.57 |
Currency in USD
